Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DL3W
|
|||
| Former ID |
DIB009954
|
|||
| Drug Name |
APX-001
|
|||
| Synonyms |
EPI-0010; SSS-07; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Apexigen; Anti-TNF alpha recombinant humanized monoclonal antibody (RabMab/MLG, rheumatoid arthritis), 3SBio/Epitomics
Click to Show/Hide
|
|||
| Indication | Candidemia [ICD-11: 1F23.3Y; ICD-10: B37; ICD-9: 112] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Investigative | [2] | ||
| Company |
Epitomics Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H21N4O6P
|
|||
| Canonical SMILES |
C1=CC=NC(=C1)OCC2=CC=C(C=C2)CC3=NOC(=C3)C4=C([N+](=CC=C4)COP(=O)(O)[O-])N
|
|||
| InChI |
1S/C22H21N4O6P/c23-22-19(4-3-11-26(22)15-31-33(27,28)29)20-13-18(25-32-20)12-16-6-8-17(9-7-16)14-30-21-5-1-2-10-24-21/h1-11,13,23H,12,14-15H2,(H2,27,28,29)
|
|||
| InChIKey |
JQONJQKKVAHONF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 2091769-17-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03604705) An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia. U.S. National Institutes of Health. | |||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.